AI Science Tracker

Machine-learning-guided peptide design yielded non-hemolytic anticancer candidates

University of Bern · 5 Aug 2022 · medicine

Discovery

Machine-learning-guided peptide design yielded non-hemolytic anticancer candidates

A recurrent neural network generated peptide sequences and classified predicted activity and hemolysis; a genetic-algorithm route also generated analogues. After sequence and physicochemical filters, researchers synthesized and tested 33 peptides. The paper reports 11 active anticancer peptides in its cell assays, four non-hemolytic under its red-cell assay. These in-vitro results do not establish cancer-cell specificity, clinical safety or therapeutic efficacy. A related 2020 modeling paper is separate from this experimental study; no claim of absolute sequence novelty is made.

Technology: Generative recurrent neural network, genetic algorithm, and recurrent-neural-network activity and hemolysis classifiers

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The abstract reports that 33 peptides were experimentally evaluated, 11 were active in anticancer cell assays, and four of the active peptides were non-hemolytic in the reported assays.
  • Still unknown: In-vitro activity and red-cell hemolysis do not establish cancer-cell specificity, clinical safety or treatment efficacy. Detailed potency measurements and absolute sequence novelty were not reassessed in this bounded review.
  • AI role: RNN and genetic-algorithm generation with RNN activity and hemolysis classifiers guided peptide selection for synthesis and testing.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/35880810/ · https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202200291

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary publisher metadata and primary PubMed abstract/affiliation block; full PMC endpoint returned a browser verification challenge in this review..

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.